Article
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Cancer discovery - 1 Jul 2015
Piotrowska Zofia, Niederst Matthew J, Karlovich Chris A, Wakelee Heather A, Neal Joel W, Mino-Kenudson Mari, Fulton Linnea, Hata Aaron N, Lockerman Elizabeth L, Kalsy Anuj, Digumarthy Subba, Muzikansky Alona, Raponi Mitch, Garcia Angel R, Mulvey Hillary E, Parks Melissa K, DiCecca Richard H, Dias-Santagata Dora, Iafrate A John, Shaw Alice T, Allen Andrew R, Engelman Jeffrey A, Sequist Lecia V
Abstract excerpt
UNLABELLED: Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied patients at rociletinib progression to explore resistance mechanisms. Among 12 patients with T790M-positive cancers at rociletinib initiation, six had T790-wild-type rociletinib-resistant biopsies. Two T790-wild-type cancers...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.